• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients.

作者信息

Patoulias Dimitrios, Papadopoulos Christodoulos, Stavropoulos Konstantinos, Imprialos Konstantinos, Doumas Michael

机构信息

Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.

Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.

出版信息

Am J Cardiol. 2020 Dec 15;137:133-135. doi: 10.1016/j.amjcard.2020.10.004. Epub 2020 Oct 9.

DOI:10.1016/j.amjcard.2020.10.004
PMID:33045202
Abstract
摘要

相似文献

1
Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients.
Am J Cardiol. 2020 Dec 15;137:133-135. doi: 10.1016/j.amjcard.2020.10.004. Epub 2020 Oct 9.
2
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis.胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者主要不良心血管事件的影响：按种族、民族和地区进行的荟萃分析
Medicine (Baltimore). 2020 Dec 4;99(49):e23489. doi: 10.1097/MD.0000000000023489.
3
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管疗效和安全性：系统评价和网络荟萃分析。
Diabet Med. 2019 Apr;36(4):444-452. doi: 10.1111/dme.13898. Epub 2019 Jan 30.
4
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
5
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
6
Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.胰高血糖素样肽-1 受体激动剂与心血管事件：类别效应与个体模式。
Trends Endocrinol Metab. 2018 Apr;29(4):238-248. doi: 10.1016/j.tem.2018.01.011. Epub 2018 Feb 17.
7
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在心血管和肾脏保护方面的作用：一种超越降血糖作用的治疗方法。
Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17.
8
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
9
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.2 型糖尿病合并心血管疾病患者的降糖治疗。
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):73-80. doi: 10.1177/2047487319880040.
10
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.基于随机对照试验的系统评价和荟萃分析：相较于单独使用钠-葡萄糖共转运蛋白 2 抑制剂，胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖共转运蛋白 2 抑制剂在血糖疗效和安全性方面的表现。
Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13.

引用本文的文献

1
Central and peripheral arterial stiffness and sarcopenia in hospitalized older adults.住院老年人的中心和外周动脉僵硬度与肌肉减少症
Aging Clin Exp Res. 2025 Jul 19;37(1):223. doi: 10.1007/s40520-025-03122-4.
2
Arterial Stiffness, Subendocardial Impairment, and 30-Day Readmission in Heart Failure Older Patients.老年心力衰竭患者的动脉僵硬度、心内膜下损伤与30天再入院情况
Front Cardiovasc Med. 2022 Jun 17;9:918601. doi: 10.3389/fcvm.2022.918601. eCollection 2022.